Promoting the term MAFLD: China in action

Changing the term non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease (MAFLD) has gained increasing traction from numerous international and regional societies, including the Asian Pacific Association for the Study of the Liver, the Latin American Association for the Study of the Liver, the Chinese Society of Hepatology, the Malaysian Society of Gastroenterology and Hepatology, and the Arabic Association for the Study of Diabetes and Metabolism. Simultaneously, key stakeholders, such as policy makers, hepatologists, endocrinologists, nutritionists, the pharmaceutical industry, nurses, and patient advocates, have indicated strong support for this new term.